Released Aug 12, 2024, before the open
10-Q filed Aug 12, 2024, 43 days after period end · 0001171843-24-004670
Q2 2024 · 10-Q
Revenue$850.00K$850.00K — vs Q2 2023no prior Q1 2024 on file
Net Income-$13.08M-$13.08M N/M vs Q2 2023N/M vs Q1 2024
EPS, diluted—
Operating Income-$15,045,000N/M
Operating Cash Flowderived-$10,754,000N/M
Free Cash Flowderived-$10,754,000N/M
Margins · derived
Operating margin-1770.0%
Net margin-1538.4%
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $850.00K | $0.00 | — | — |
| Net Income | -$13.08M | -$11.28M | -$8.49M | -$55.80M |
| EPS Diluted | — | — | — | -$1.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR